Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on Preoperative Treatment with Amivantamab, Carboplatin, and Pemetrexed for Patients with Resectable Non-Small-Cell Lung Cancer with EGFR Mutations

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying treatments for a type of lung cancer known as non-small-cell lung cancer that has specific genetic changes called EGFR mutations. The study will explore the use of a medication called amivantamab, which is given as an infusion into the vein. In some cases, amivantamab will be used alone, and in others, it will be combined with two chemotherapy drugs, carboplatin and pemetrexed disodium. The purpose of the study is to see if these treatments can be given safely before surgery to remove the cancer.

Participants in the study will receive treatment with amivantamab for four weeks. In the first stage, amivantamab will be given by itself. In the second stage, it will be combined with carboplatin and pemetrexed disodium. After the treatment, patients will undergo surgery to remove the cancer. If needed, additional treatments such as chemotherapy, radiation therapy, or medications targeting EGFR mutations may be provided after surgery.

The study aims to determine if this approach is feasible and safe for patients with early-stage or locally advanced non-small-cell lung cancer that can be surgically removed. The study will also look at how the cancer responds to the treatment and how it affects the patient's health and recovery after surgery.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initiation of treatment

    Upon joining the study, the patient will begin the treatment phase. This involves receiving amivantamab as a single therapy. The medication is administered through an intravenous infusion, which means it is delivered directly into the bloodstream through a vein.

    This phase lasts for four weeks, during which the patient will receive the infusion at regular intervals as determined by the study protocol.

  2. Step 2

    Combination therapy

    Following the initial phase, the patient will receive a combination of amivantamab, carboplatin, and pemetrexed. These medications are also administered via intravenous infusion.

    The combination therapy is designed to enhance the treatment's effectiveness against non-small-cell lung cancer with specific genetic mutations.

  3. Step 3

    Surgical intervention

    After completing the medication phases, the patient will undergo surgery to remove the lung cancer. This is a standard procedure aimed at achieving a curative outcome.

    The surgery is planned to occur within 43 days of starting the study therapy, depending on the patient's response and overall health condition.

  4. Step 4

    Post-surgery care

    Following surgery, the patient may receive additional treatments if necessary. These could include chemotherapy, radiotherapy, or targeted therapy with EGFR tyrosine kinase inhibitors, depending on the clinical indications.

    The goal of these treatments is to eliminate any remaining cancer cells and reduce the risk of recurrence.

  5. Step 5

    Follow-up and monitoring

    The patient will be monitored regularly to assess their recovery and the effectiveness of the treatment. This includes routine check-ups and imaging studies to evaluate the disease status.

    The follow-up period is crucial for ensuring the patient's well-being and addressing any potential complications that may arise after the treatment.

Who can join the trial?

14 criteria

  • Patients must have **non-small-cell lung cancer** that is confirmed through a biopsy. This type of cancer affects the lungs and is not the small cell type.
  • The cancer must be at specific stages: **Stage I B, II, or selected Stage III A**. These stages describe how much the cancer has spread.
  • Patients must have a specific change in their cancer called an **oncogenic EGFR mutation**. This is a change in the cancer cells that can be targeted by certain treatments.
  • Patients must be able to have surgery to remove the cancer.
  • Patients must be 18 years or older.
  • Patients must be able to understand and agree to the study by signing a consent form.
  • Patients must have a good **ECOG performance status** of 0 or 1, which means they are fully active or have some symptoms but can still do light work.
  • Patients must not have cancer that has spread to many lymph nodes in the chest or to other parts of the body.
  • Patients must have a tumor that can be measured using imaging techniques.
  • Patients must have good lung function to safely undergo lung surgery.
  • Patients must have normal blood, liver, and kidney function. This includes having enough blood cells and normal levels of substances in the blood.
  • Patients must have a healthy heart with a **left ventricular ejection fraction (LVEF)** of 50% or higher, which measures how well the heart pumps blood.
  • Women who can have children must have a negative pregnancy test and agree to use birth control during the study and for 6 months after.
  • Men must agree to use condoms during the study and for 6 months after, and not donate sperm during this time.

Who cannot join the trial?

8 criteria

  • Patients with other types of cancer besides the specific type of lung cancer being studied.
  • Patients who do not have the specific genetic change called **EGFR mutation** in their cancer.
  • Patients who are not in the early or locally advanced stages of the specific lung cancer being studied.
  • Patients who are not eligible for surgery to remove the cancer.
  • Patients who have received certain treatments for cancer that might interfere with the study.
  • Patients with serious health conditions that could make it unsafe for them to participate.
  • Patients who are pregnant or breastfeeding.
  • Patients who are unable to follow the study procedures or attend required visits.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Amivantamab

    is an antibody therapy used in this trial to treat patients with non-small-cell lung cancer that has specific genetic changes known as EGFR mutations. It is given before surgery to see if it can help shrink the tumor and make it easier to remove.

  • Carboplatin

    is a type of chemotherapy used in combination with other medications to treat cancer. In this trial, it is combined with amivantamab and pemetrexed to see if the combination is more effective in treating non-small-cell lung cancer before surgery.

  • Pemetrexed

    is another chemotherapy drug used in this trial. It works by stopping the growth of cancer cells. When used with carboplatin and amivantamab, it aims to enhance the treatment's effectiveness in shrinking the tumor before surgery.

What is already known about the treatment

Amivantamab – Amivantamab is administered intravenously and is currently being studied for its effectiveness in treating non-small-cell lung cancer with specific EGFR mutations. It is in the clinical trial phase, exploring its use both as a standalone treatment and in combination with chemotherapy drugs like carboplatin and pemetrexed. The main therapeutic indication is for patients with resectable non-small-cell lung cancer at certain stages. Amivantamab works by targeting and binding to the EGFR and MET receptors on cancer cells, blocking signals that promote tumor growth. It is classified as a monoclonal antibody, which is a type of targeted cancer therapy.

Investigated diseases

Non-small-cell lung cancer – This is a type of lung cancer that includes several subtypes such as adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. It is characterized by the uncontrolled growth of cells in the lung tissues, which can form tumors. The disease progresses through stages, starting from localized tumors in the lung (stage I) to more advanced stages where cancer spreads to nearby lymph nodes or other parts of the body (stages II and III). In some cases, specific genetic mutations, such as the EGFR mutation, can drive the growth of cancer cells. These mutations can influence the behavior of the cancer and its response to certain therapies. The progression of the disease can vary based on the stage at diagnosis and the presence of specific genetic mutations.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IITrial ID2023-505662-28-00Protocol code61186372NSC2008Estimated enrolment25 patientsSponsorUniversitaetsklinikum Essen AöR

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.